French consensus: Augmentation syndrome in restless legs syndrome.

S Leu-Semenescu, C Petiau, C Charley Monaca, Y Dauvilliers

Journal: Revue neurologique 2018;174(7-8):532-539

PMID: 30055794

Abstract

Augmentation syndrome is one of the most severe complications of RLS. It is characterised by a worsening of treated symptoms; principally an increase in the severity of symptoms and an earlier onset time. Augmentation syndrome occurs primarily with dopaminergic treatments. It is crucial for the patient to be sufficiently well informed to prevent its occurrence and the prescription of too high doses of dopaminergic agonists avoided. In the presence of augmentation syndrome confirmed using the diagnostic criteria, the specialist treating the restless legs syndrome should quickly modify the patient's treatment. In this article, our expert group proposes a practical strategy for the diagnosis, prevention and treatment of augmentation syndrome.

Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Address: Narcolepsy and Idiopathic Hypersomnia National Reference Centre, 75000 Paris, France; Sleep pathologies Service, Pitié-Salpêtrière/Charles-Foix, AP-HP Hospital Group, 75651 Paris cedex 13, France; The Brain and Spinal Institute Research Centre, UPMC Paris 6, Inserm U1127, CNRS UMR7225, 75000 Paris, France. Electronic address: [email protected].; Sainte-Barbe Clinical Sleep Centre, Saint-Vincent Hospital Group, 67000 Strasbourg, France.; Clinical Neurophysiology, Teaching Hospital, Lille University, Inserm UMR 1171, 59037 Lille, France.; Narcolepsy and Idiopathic Hypersomnia National Reference Centre, 75000 Paris, France; Neurology Department, Sleep disorders Unit, Gui-De-Chauliac Hospital, 34295 Montpellier, France; Inserm U1061, UM1, 34295 Montpellier, France.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.